AGC Pharma Chemicals Announces a Strategic Partnership with CatSci Ltd

AGC Pharma Chemicals Announces a Strategic Partnership with CatSci Ltd

AGC Pharma Chemicals, recognized in the market as a global Contract Development and Manufacturing Organization (CDMO) producing small molecule APIs and intermediate products, announces a new strategy in its business through a partnership with CatSci, an award-winning strategic partner for end-to-end non-clinical development of new therapeutics.

This will enable AGC Pharma Chemicals’s customers to harness expertise in state-of-the-art chemical development, analytical development, crystallisation and solid form, preformulation and high potency API capabilities alongside CMC capability for the development of their new therapeutics. Streamlined tech transfer workflows will ensure a seamless process knowledge and information transfer from development to manufacturing.

AGC Pharma Chemicals has more than 40 years’ experience as a small molecule CDMO and 60 years as API manufacture. They offer to the customers tailored solutions in terms of development and manufacturing, from early clinical phase through to the commercial stage. They provide a reliable, flexible and agile services.  AGC Pharma Chemicals also offers high-quality chemical compounds by developing cost-efficient manufacturing processes in full compliance with environmental, health and safety, and cGMP international standards.

CatSci is a trusted partner for end-to-end non-clinical development of new therapeutics. Based in Cardiff, they proudly serve customers across the globe developing economically and environmentally sustainable processes that support pharmaceutical innovators at all stages of the drug development timeline. By providing perfect-for-purpose solutions, CatSci helps their global customers to navigate complex scientific challenges and address critical healthcare needs, including antimicrobial resistance, cancer, and mental health.

With an alignment in values, AGC Pharma Chemicals and CatSci have created an alliance of trust to add strategic value to their customers’ drug development journey. They will work together to provide scalable small molecule API manufacturing, from grams to tons, meeting the requisite quality, timelines and budget to support projects from pre-clinical development to large-scale commercial production. Through this partnership, customers will get access to a wide range of manufacturing technologies including fluorination, bromination, hydrogenation, cryogenic, HPAPI, micronization and continuous flow to support their complex manufacturing programs.

This strategical partnership is integrated into the AGC Pharma Chemicals’ continuous growth plan. Offering a one-stop shop service to customers, who can handle the lifecycle management of small molecules from grams to tons and from clinical phase to commercialization, will expedite the delivery of life-changing new medicines to patients worldwide.

Hiro Kadokura, AGC Pharma Chemicals Europe’s Chief Executive Officer, said: “It is great to have CatSci as a partner of AGC Pharma Chemicals, as we can provide seamless service to our customers from pre-clinical to the launch.  Together with the strong cGMP CDMO capability of AGC Pharma Chemicals, and the excellent CRO capability of CatSci, we can cover especially early phase projects leveraging the effective expertise of each company. I am excited about this partnership that will bring great value to our customers.” 

Dr Jérôme Theobald, CatSci’s Chief Operating Officer, said: “I am thrilled that CatSci is partnering with AGC Pharma Chemicals; they are a leading small molecule CDMO with 40 years’ experience and CatSci are excited about what our partnership means for our customers. I am confident that AGC’s excellent cGMP manufacturing capabilities will add strategic value to our customers’ pipeline, accelerating their path to clinic. At CatSci, we are driven by our purpose to get new medicines into the hands of patients in need, and it was clear from the start that AGC Pharma Chemicals are aligned with us on this goal. Our partnership is built on our commitment to solve our customers’ challenges, allowing them to advance seamlessly through their pharmaceutical development from drug substance to drug product.”

For more information, including media enquiries, please contact:

AGC Pharma Chemicals – Guillermina Riva:

CatSci Ltd – Caitlin Bourton:


About AGC Pharma Chemicals

AGC Pharma Chemicals based in Spain and Japan, is covering the strong demand of the industry, focusing on their mission: to improve people´s lives by bringing their best quality products. The company is an innovative Contract Development and Manufacturing Organization (CDMO) serving the global pharmaceutical industry with small molecule APIs and intermediates.

AGC Pharma Chemicals has a solid business growth and financial stability as a part of AGC Group, formerly Asahi Glass Company. AGC Group is a global business conglomerate with over 200 companies, more than 55,800 employees and extending into over 30 countries with net sales of € 12,731 million (Y120 = €1) during 2021.


About CatSci Ltd

CatSci Ltd is an award-winning innovation partner, dedicated to breaking down the silos in drug development to accelerate the delivery of life-changing medicines to patients in need. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies including catalysis, material science, pre-formulation, analytical development and HPAPI development.

Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class small molecule therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world.

Recent recognition includes the highly esteemed Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees) and STEM Ambassador of the Year), and the 2022 Cardiff Business Award (International Business of the Year).

Contact us: